Superficial Thrombophlebitis

Order compression venous ultrasonography for lower-extremity SVT at presentation. Image the symptomatic superficial vein to document thrombus location and extent, and examine the deep venous system; bilateral compression ultrasonography is recommended to detect concomitant venous thromboembolic disease. PubMed+1PubMedSuperficial Vein Thrombosis - StatPearls - NCBI BookshelfPubMedTreatment of Superficial Vein Thrombosis: Recent Advances, Unmet ... Ultrasound findings supporting SVT include a noncompressible superficial vein, intraluminal thrombus, and absent color Doppler flow; soft-tissue edema and vein-wall thickening may accompany the thrombus. Wolters Kluwer+1Wolters KluwerUltrasound in Superficial Thrombophlebitis:... : Journal of Emergencies, Trauma, and ShockScienceDirectSeptic Thrombophlebitis - an overview

Treat dyspnea, pleuritic chest pain, syncope, hypoxemia, or hemodynamic instability as possible PE rather than uncomplicated SVT. Concurrent DVT is particularly consequential when thrombus reaches the saphenofemoral junction: 11% to 40% of patients with SVT at that junction have reported concurrent DVT. ScienceDirect+1ScienceDirectVein Superficial Thrombosis - an overviewScienceDirectSuperficial Vein Thrombosis - an overview | ScienceDirect Topics A confirmed DVT changes management from isolated-SVT treatment to therapeutic anticoagulation for venous thromboembolism.

Document three features from the ultrasound report before selecting therapy: thrombus length, involved vein, and distance to the saphenofemoral or saphenopopliteal junction. Clinical erythema can underestimate thrombus extent, particularly when disease approaches a deep-venous junction. ScienceDirectScienceDirectSeptic Thrombophlebitis - an overview

Anticoagulation is generally favored for lower-extremity SVT at least 5 cm in length, disease proximal to the knee, severe symptoms, great saphenous involvement, prior SVT or VTE, active malignancy, or recent surgery. PubMedPubMedSuperficial Vein Thrombosis - StatPearls - NCBI Bookshelf Additional progression-risk features include pregnancy, hormonal exposure, and active inflammatory disease. ASHASHSuperficial Thrombophlebitis: The Less Dangerous Cousin of Deep Vein Thrombosis That Can Still Cause Harm | The Hematologist | American Society of Hematology These factors should move management away from NSAID-only treatment even when no DVT is found initially.

An SVT endpoint less than 3 cm from the saphenofemoral junction is a high-risk anatomic pattern. ASHASHSuperficial Thrombophlebitis: The Less Dangerous Cousin of Deep Vein Thrombosis That Can Still Cause Harm | The Hematologist | American Society of Hematology BMJ guidance similarly identifies thrombus near the saphenofemoral or saphenopopliteal junction as an indication to consider anticoagulation or surgical ligation. BMJBMJSuperficial thrombophlebitis (superficial venous thrombosis) | The BMJ Do not classify this anatomy as routine isolated distal SVT.

Varicose veins support a local venous cause, but their presence does not eliminate thromboembolic risk. In patients with SVT at the saphenofemoral junction, concurrent DVT has been reported less often with varicose veins than without them, 20% versus 60% in cited data. ScienceDirect+1ScienceDirectVein Superficial Thrombosis - an overviewScienceDirectSuperficial Vein Thrombosis - an overview | ScienceDirect Topics Therefore, absence of varicosities should heighten attention to concurrent VTE and systemic provoking factors rather than reassure.

For anticoagulation-eligible isolated lower-extremity SVT, use fondaparinux 2.5 mg subcutaneously once daily for 45 days when not contraindicated. PubMed+1PubMedSuperficial Vein Thrombosis - StatPearls - NCBI BookshelfASHSuperficial Thrombophlebitis: The Less Dangerous Cousin of Deep Vein Thrombosis That Can Still Cause Harm | The Hematologist | American Society of Hematology Fondaparinux reduced symptomatic VTE compared with placebo in randomized evidence and also reduces extension or recurrence. acpjournals+1acpjournalsReview: Fondaparinux reduces VTE and recurrence in superficial ...ASHSuperficial Thrombophlebitis: The Less Dangerous Cousin of Deep Vein Thrombosis That Can Still Cause Harm | The Hematologist | American Society of Hematology This regimen is particularly applicable to symptomatic above-knee SVT not involving the saphenofemoral junction. ScienceDirectScienceDirectSuperficial Vein Thrombosis - an overview | ScienceDirect Topics

Rivaroxaban 10 mg orally once daily was noninferior to fondaparinux in the SURPRISE trial population with SVT plus additional risk factors, and a comparison summarized by ASH found no difference in symptomatic VTE or SVT extension between rivaroxaban 10 mg daily and fondaparinux 2.5 mg daily. The Lancet+1The Lancetthe open-label, randomised, non-inferiority SURPRISE phase 3b trialASHSuperficial Thrombophlebitis: The Less Dangerous Cousin of Deep Vein Thrombosis That Can Still Cause Harm | The Hematologist | American Society of Hematology Consider rivaroxaban when an oral regimen is preferred and patient-specific renal function, drug interactions, bleeding risk, and labeled use are suitable; evidence for this approach in SVT is less extensive than for fondaparinux. ASHASHSuperficial Thrombophlebitis: The Less Dangerous Cousin of Deep Vein Thrombosis That Can Still Cause Harm | The Hematologist | American Society of Hematology

LMWH at prophylactic doses for 30 days is an alternative described by NICE, but that indication is off-label. cks nice org ukcks nice org ukScenario: Management of superficial vein thrombosis - CKS - NICE Evidence synthesis indicates that LMWH reduces SVT extension, whereas only fondaparinux reduced symptomatic VTE versus placebo in the summarized trials. ASHASHSuperficial Thrombophlebitis: The Less Dangerous Cousin of Deep Vein Thrombosis That Can Still Cause Harm | The Hematologist | American Society of Hematology Therefore, choose LMWH chiefly when fondaparinux is unsuitable and a parenteral alternative is needed.

Do not substitute topical therapies, compression, or surgery for anticoagulation when the purpose is prevention of DVT or PE in higher-risk SVT. Topical treatments improve local symptoms but have inadequate data for VTE or SVT-extension outcomes; surgical evidence is limited and insufficient to guide routine thrombotic-risk management. PubMedPubMedTreatment of Superficial Vein Thrombosis: Recent Advances, Unmet ...

Manage limited below-knee SVT without DVT using an NSAID and compression when there are no high-risk anatomic or clinical features. BMJBMJSuperficial thrombophlebitis (superficial venous thrombosis) | The BMJ NSAIDs reduce SVT extension in trial evidence, but fondaparinux—not NSAIDs—reduced symptomatic VTE compared with placebo in the summarized randomized evidence. ASHASHSuperficial Thrombophlebitis: The Less Dangerous Cousin of Deep Vein Thrombosis That Can Still Cause Harm | The Hematologist | American Society of Hematology Explain this distinction when choosing symptom-directed treatment rather than anticoagulation.

Compression and local symptom measures can reduce discomfort, but they should not delay ultrasound or replace anticoagulation when thrombus is extensive, proximal, or close to a deep-venous junction. BMJ+1BMJSuperficial thrombophlebitis (superficial venous thrombosis) | The BMJPubMedTreatment of Superficial Vein Thrombosis: Recent Advances, Unmet ... Repeat examination and reassess the treatment plan for increasing pain, expanding erythema, extension of a palpable cord, or new cardiopulmonary symptoms; thrombus propagation despite medical treatment is a reason to consider surgery or anticoagulation escalation. BMJBMJSuperficial thrombophlebitis (superficial venous thrombosis) | The BMJ

Do not routinely investigate every patient with SVT for inherited thrombophilia or occult malignancy. PubMedPubMedSuperficial Vein Thrombosis - StatPearls - NCBI Bookshelf Instead, identify whether the event is recurrent, unprovoked, migratory, bilateral, or occurring without varicose veins, because these patterns increase concern for systemic thrombotic drivers and should also prompt meticulous evaluation for DVT and PE. ScienceDirect+2ScienceDirectVein Superficial Thrombosis - an overviewScienceDirectSuperficial Vein Thrombosis - an overview | ScienceDirect TopicsPubMedMigratory Thrombophlebitis - StatPearls - NCBI Bookshelf

Migratory thrombophlebitis warrants investigation for visceral malignancy. PubMed+1PubMedSuperficial Vein Thrombosis - StatPearls - NCBI BookshelfPubMedMigratory Thrombophlebitis - StatPearls - NCBI Bookshelf This pattern consists of recurrent superficial inflammatory-thrombotic lesions at changing sites and may represent Trousseau syndrome from tumor-driven hypercoagulability. PubMedPubMedMigratory Thrombophlebitis - StatPearls - NCBI Bookshelf In this setting, pursue an age- and risk-appropriate malignancy evaluation rather than treating repeated episodes as isolated local venous inflammation.

Consider septic thrombophlebitis when local venous thrombosis is accompanied by systemic infectious features or concern for purulence. Septic disease includes infection of the thrombus and can involve purulent intraluminal material, vein necrosis, and periphlebitic abscess; evaluation incorporates examination, blood studies, and duplex ultrasonography. ScienceDirectScienceDirectSeptic Thrombophlebitis - an overview This pattern requires infection-directed management rather than NSAID-only treatment.

Upper-extremity SVT is less likely than lower-extremity SVT to progress to DVT, but ultrasound remains useful when thrombus extent or deep-system involvement is uncertain. ScienceDirectScienceDirectSeptic Thrombophlebitis - an overview Pregnancy is a progression-risk feature in SVT, and postpartum occurrence is notable; involve obstetric and thrombosis expertise when anticoagulant selection is needed. PubMed+1PubMedSuperficial Thrombophlebitis - StatPearls - NCBI BookshelfASHSuperficial Thrombophlebitis: The Less Dangerous Cousin of Deep Vein Thrombosis That Can Still Cause Harm | The Hematologist | American Society of Hematology